Skip to main content
SpringerLink
Log in

Infusion reactions are common following administration of cetuximab and rituximab, leading to an increase in treatment costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Schwartzberg LS, Stepanski EJ, Walker MS, Mathias S, Houts AC, Fortner BV.Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Supportive Care in Cancer 17: 91-98, No. 1, Jan 2009

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Infusion reactions are common following administration of cetuximab and rituximab, leading to an increase in treatment costs. Pharmacoecon. Outcomes News 573, 9 (2009). https://doi.org/10.2165/00151234-200905730-00027

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905730-00027

Keywords

Search

Navigation